Evidence map›Paper›PMID 35483010›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.

Julio Garcia-Aguilar, Sujata Patil, Marc J Gollub, Jin K Kim, Jonathan B Yuval, Hannah M Thompson, Floris S Verheij, Dana M Omer, Meghan Lee, Richard F Dunne and 32 more

5 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 545 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
545citing papers in PubMed, 11 pooled it
82.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06631443 recruitingnot on this mapstarted 2024, after this paper: background citation

Evaluation of Clinical Outcome in Asian Patients with Localized Rectal Adenocarcinoma Managed with Watch-and-wait Approach by Developing a Multinational Collaborative Database.

Typeobservational_patient_registrySponsorTata Memorial CentreRan2024 to 2029Enrolled337ConditionsRectal Adenocarcinoma, Rectal Cancer
NCT07173387 phase2active not recruitingnot on this mapstarted 2025, after this paper: background citation

Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer: A Prospective Clinical Trial

TypeinterventionalSponsorShandong Cancer Hospital and InstituteRan2025 to 2028Enrolled42ConditionsPancreatic CancerArmsNALIRIFOX (liposomal irinotecan-based chemotherapy)., Stereotactic Body Radiation Therapy (SBRT).
NCT07372300 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

The Efficacy of Combination of Modulated Electro-Hyperthermia(mEHT) in The Multimodality Management in Locally Advanced Rectal Cancer: A Multicenter Phase 3 Randomized Control Trial.

TypeinterventionalSponsorShih-Kai HungRan2025 to 2027Enrolled126ConditionsLocally Advanced Rectal CarcinomaArmsHyperthermia
NCT07521605 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Short-Course Radiotherapy Followed by Liposomal Irinotecan, Capecitabine, and Camrelizumab as Neoadjuvant Therapy for Locally Advanced pMMR/MSS Low Rectal Cancer: A Prospective Single-Arm Phase II Trial Protocol

TypeinterventionalSponsorGuangdong Provincial People's HospitalRan2026 to 2034Enrolled44ConditionsRectal Cancer PatientsArmsShort-Course Radiotherapy, Liposomal Irinotecan (nal-IRI), Capecitabine, Camrelizumab
NCT07580027 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Preoperative, Adaptive Radiotherapy Concomitant to Chemotherapy for Rectal Adenocarcinoma (Adaptive Rectal Cancer Trial 02). An Interventional Study.

TypeinterventionalSponsorIRCCS San RaffaeleRan2026 to 2029Enrolled33ConditionsLocally Advanced Rectal CarcinomaArmsPreoperative, adaptive radiotherapy
3 · Its place in the literature

Who cites it

545 citing papers in PubMed, 11 syntheses or guidelines pooled it, 843 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

485 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

42 authors at 20 institutions in 1 country.

Julio Garcia-AguilarDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-2451-0948
Sujata PatilDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Marc J GollubDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-6008-0730
Jin K KimDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Jonathan B YuvalDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9251-8303
Hannah M ThompsonDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Floris S VerheijDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-7834-7336
Dana M OmerDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Meghan LeeDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Richard F DunneDepartment of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.ORCID 0000-0001-6608-660X
Jorge MarcetDivision of Colon and Rectal Surgery, Department of Surgery, University of South Florida, Tampa, FL.ORCID 0000-0003-3728-8741
Peter CataldoDivision of General Surgery, Department of Surgery, University of Vermont, Burlington, VT.
Blase PoliteDepartment of Medicine, Comprehensive Cancer Center, University of Chicago, Chicago, IL.ORCID 0000-0001-8743-8096
Daniel O HerzigDivision of Gastrointestinal and General Surgery, Oregon Health and Science University, Portland, OR.
David LiskaDepartment of Colorectal Surgery, Cleveland Clinic, Cleveland, OH.ORCID 0000-0002-8632-6065
Samuel OommenDivision of Gastrointestinal Oncology, John Muir Cancer Institute, John Muir Health, Walnut Creek, CA.
Charles M FrielDivision of General Surgery, Department of Surgery, University of Virginia, Charlottesville, VA.
Charles TernentDepartment of Surgery, Colorectal Service at Bergan Mercy Medical Center, Omaha, NE.ORCID 0000-0003-0050-9723
Andrew L CovelerDepartment of Medicine, Fred Hutch Cancer Center, University of Washington, Seattle, WA.ORCID 0000-0003-1710-5637
Steven HuntDepartment of Surgery, Washington University School of Medicine, St Louis, MO.
Anita GregoryDepartment of Surgery, St Joseph Hospital Orange County, Orange, CA.
Madhulika G VarmaSection of Colon and Rectal Surgery, Department of Surgery, University of California, San Francisco, San Francisco, CA.ORCID 0000-0003-1679-926X
Brian L BelloDivision of Colorectal Surgery, Department of Surgery, Medstar Washington Hospital Center, Washington, DC.
Joseph C CarmichaelDivision of Colon and Rectal Surgery, Department of Surgery, University of California, Irvine, Irvine, CA.ORCID 0000-0003-2738-7113
John KraussDepartment of Medicine, Rogel Cancer Center at the University of Michigan, Ann Arbor, MI.ORCID 0000-0002-5197-736X
Ana GleisnerDivision of Surgical Oncology, Department of Surgery, University of Colorado, Denver, CO.ORCID 0000-0002-5040-4105
Philip B PatyDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-7045-2112
Martin R WeiserDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9577-7984
Garrett M NashDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Emmanouil PappouDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.
José G GuillemDivision of Gastrointestinal Surgery, Department of Surgery, University of North Carolina, Chapel Hill, NC.
Larissa TempleDivision of Colorectal Surgery, Department of Surgery, University of Rochester Medical Center, Rochester, NY.
Iris H WeiDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-9006-9105
Maria WidmarDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Sabrina LinDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-7535-2535
Neil H SegalDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-3047-2303
Andrea CercekDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-5054-8192
Rona YaegerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-7233-5454
J Joshua SmithDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0003-2538-5456
Karyn A GoodmanDepartment of Radiation Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.ORCID 0000-0002-4576-6355
Abraham J WuDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-2597-7091
Leonard B SaltzDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-8353-4670
Memorial Sloan Kettering Cancer Center · USUniversity of Rochester Medical Center · USCleveland Clinic · USIcahn School of Medicine at Mount Sinai · USJohn Muir Health · USMedStar Washington Hospital Center · USMercy Medical Center · USOregon Health & Science University · USSt. Joseph Hospital · USUniversity of California, Irvine · USUniversity of California, San Francisco · USUniversity of Chicago · USUniversity of Colorado Denver · USUniversity of Michigan · USUniversity of North Carolina at Chapel Hill · USUniversity of South Florida · USUniversity of Vermont · USUniversity of Virginia · USUniversity of Washington · USWashington University in St. Louis · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
SURGICAL ONCOLOGY RESEARCH TRAINING PROGRAMT32CA009501 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Babak J Mehrara · 1985 to 2026
$7.7M
Organ Preservation in Rectal AdenocarcinomaR01CA182551 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI GARCIA-AGUILAR, JULIO · 2014 to 2018
$3.1M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA182551NCI NIH HHS T32 CA009501
6 · The paper itself

Abstract

purposeProspective data on the efficacy of a watch-and-wait strategy to achieve organ preservation in patients with locally advanced rectal cancer treated with total neoadjuvant therapy are limited.

methodsIn this prospective, randomized phase II trial, we assessed the outcomes of 324 patients with stage II or III rectal adenocarcinoma treated with induction chemotherapy followed by chemoradiotherapy (INCT-CRT) or chemoradiotherapy followed by consolidation chemotherapy (CRT-CNCT) and either total mesorectal excision (TME) or watch-and-wait on the basis of tumor response. Patients in both groups received 4 months of infusional fluorouracil-leucovorin-oxaliplatin or capecitabine-oxaliplatin and 5,000 to 5,600 cGy of radiation combined with either continuous infusion fluorouracil or capecitabine during radiotherapy. The trial was designed as two stand-alone studies with disease-free survival (DFS) as the primary end point for both groups, with a comparison to a null hypothesis on the basis of historical data. The secondary end point was TME-free survival.

resultsMedian follow-up was 3 years. Three-year DFS was 76% (95% CI, 69 to 84) for the INCT-CRT group and 76% (95% CI, 69 to 83) for the CRT-CNCT group, in line with the 3-year DFS rate (75%) observed historically. Three-year TME-free survival was 41% (95% CI, 33 to 50) in the INCT-CRT group and 53% (95% CI, 45 to 62) in the CRT-CNCT group. No differences were found between groups in local recurrence-free survival, distant metastasis-free survival, or overall survival. Patients who underwent TME after restaging and patients who underwent TME after regrowth had similar DFS rates.

conclusionOrgan preservation is achievable in half of the patients with rectal cancer treated with total neoadjuvant therapy, without an apparent detriment in survival, compared with historical controls treated with chemoradiotherapy, TME, and postoperative chemotherapy.

Indexed as

AdenocarcinomaRectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCapecitabineChemoradiotherapyDisease-Free SurvivalFluorouracilHumansNeoadjuvant TherapyNeoplasm StagingOrgan PreservationOxaliplatinProspective StudiesCapecitabineFluorouracilOxaliplatin

Identifiers

PMID35483010
PMCPMC9362876
OpenAlexW4225137108

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.